emetin
one
main
alkaloid
found
ipecacuanha
ipecac
root
ipecac
syrup
predominantli
use
induc
vomit
manag
poison
emetin
perhap
ipecac
ipecac
alkaloid
analogu
consid
potenti
potent
effect
therapeut
agent
coronaviru
famili
virus
particular
coronaviru
antivir
emetin
shown
amongst
lowest
valu
halfmaxim
effect
concentr
agent
screen
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronavirus
respect
outlin
rational
potenti
use
emetin
similar
compound
treatment
coronaviru
infect
confirm
vitro
sensit
analys
emetin
isol
alkaloid
use
antiinfect
agent
vedder
show
drug
kill
amoeba
vitro
one
wide
use
agent
oral
intramuscularli
treatment
intestin
extraintestin
amoebiasi
metronidazol
becam
avail
emetin
structur
unrel
metronidazol
studi
look
amount
emetin
absorb
ml
oral
dose
ipecac
contain
mg
emetin
subject
mean
plasma
concentr
h
postdos
approxim
ngml
equat
time
sar
mer
coronavirus
patient
vomit
ml
dose
emet
effect
ipecac
syrup
ml
complet
elimin
nausea
significantli
reduc
use
antagonist
ondansetron
may
enabl
higher
blood
level
achiev
result
might
initi
appear
uninspir
howev
coronavirus
predominantli
respiratori
tract
infect
amount
emetin
lung
import
plasma
oral
bioavail
studi
ipecac
alkaloid
rat
shown
concentr
radiolabel
emetin
mani
time
higher
tissu
plasma
relat
lung
h
concentr
emetin
lung
time
higher
plasma
respect
maximum
record
amount
present
lung
time
period
high
concentr
also
found
mani
tissu
liver
heart
small
larg
intestin
similarli
studi
human
strongli
indic
emetin
quickli
undergo
extens
distribut
tissu
slow
excret
detect
concentr
may
persist
urin
day
treatment
ceas
may
therefor
possibl
lung
concentr
emetin
oral
administr
ipecac
syrup
suffici
anticoronaviru
activ
especi
ipecac
alkaloid
syrup
also
antivir
properti
taken
antagonist
avoid
vomit
exampl
cephaelin
anoth
princip
alkaloid
ipecac
shown
low
nanomolar
halfmaxim
inhibitori
concentr
valu
less
zika
viru
unfortun
emetin
absorpt
oral
ipecac
display
consider
interpati
variat
patient
may
absorb
suffici
emetin
alkaloid
therapeut
effect
intramuscular
administr
emetin
number
advantag
oral
dose
emetin
undergo
metabol
liver
intramuscular
administr
would
prevent
liver
metabol
oral
absorpt
firstpass
effect
radiolabel
emetin
given
parenter
oral
administr
accumul
lung
fact
anoth
advantag
intramuscular
oral
administr
could
greater
uptak
lung
radiolabel
emetin
given
oral
rout
rat
time
point
significantli
time
emetin
found
liver
lung
convers
radiolabel
emetin
given
intraperiton
rout
guinea
pig
situat
revers
time
point
twice
much
emetin
lung
liver
could
initi
argu
reflect
interspeci
variat
like
explan
drug
absorb
intestin
circul
follow
oral
administr
first
organ
circul
goe
liver
order
foreign
compound
detoxifi
result
higher
initi
deposit
liver
proport
liver
decreas
throughout
day
redistribut
system
circul
parenter
administr
drug
enter
circulatori
system
first
organ
leav
heart
lung
result
higher
concentr
potenti
counteract
viru
intramuscular
administr
emetin
also
result
nausea
vomit
base
studi
ipecac
syrup
like
negat
concomit
use
antagonist
unlik
two
agent
would
antagonist
regard
antivir
activ
especi
emetin
high
affin
receptor
littl
activ
howev
least
consid
could
interact
vitro
studi
confirm
otherwis
sure
effect
concentr
achiev
intramuscular
rout
emetin
given
intramuscularli
establish
long
period
specif
highli
potent
agent
intestin
extraintestin
amoebiasi
emetin
entamoeba
histolytica
approxim
time
higher
sar
mer
coronavirus
impli
emetin
potenti
far
potent
anticoronaviru
agent
amoebiasi
result
may
cast
doubt
low
obtain
sar
mer
coronavirus
howev
studi
differ
author
shown
emetin
also
potent
antivir
activ
zika
viru
human
cytomegaloviru
interestingli
emetin
also
demonstr
dosedepend
inhibit
ebola
viru
virallik
particl
entri
hela
cell
emetin
abl
reduc
hiv
wild
type
multidrug
resist
infect
peripher
blood
mononuclear
cell
pbmc
hiv
revers
transcriptas
also
reduc
approxim
emetin
concentr
relat
coronavirus
emetin
activ
four
strain
coronaviru
valu
rang
mer
coronaviru
mer
viru
higher
previou
studi
indic
emetin
highli
activ
multipl
coronavirus
also
demonstr
emetin
reduc
viral
entri
cell
factor
compar
control
valu
main
therapeut
issu
emetin
use
perhap
potenti
cardiac
toxic
especi
preval
india
estim
popul
suffer
amoebiasi
result
use
emetin
widespread
lavish
emetin
use
associ
chang
electrocardiogram
ecg
particular
prolong
qt
interv
elev
st
segment
invers
wave
review
cardiac
toxic
found
therapeut
dose
mgkg
intramuscularli
maximum
mg
per
day
day
less
nonperman
cardiovascular
side
effect
occur
frequent
includ
ecg
chang
moder
hypotens
occasion
tachycardia
precordi
pain
chang
occur
treatment
complet
treatment
often
last
period
time
patient
usual
recov
without
sustain
chang
cardiovascular
function
similarli
chronic
ingest
ipecac
syrup
mani
month
suffer
bulimia
nervosa
associ
cardiac
fraction
shorten
due
cardiomyopathi
known
revert
normal
ipecac
ceas
rare
death
ipecac
syrup
overus
report
consid
substanti
higher
potenc
emetin
appear
coronaviru
dose
one
fifth
one
tenth
dose
use
treatment
amoebiasi
mgkg
intramuscularli
maximum
mgday
could
potenti
use
lower
dose
like
minimis
elimin
signific
cardiac
toxic
nausea
maintain
antivir
effect
also
note
intraven
rout
consid
toxic
offer
therapeut
advantag
appropri
pharmaceut
refer
list
consult
clinic
use
patient
formul
test
emetin
inject
unit
state
pharmacopoeia
british
pharmacopoeia
bp
list
emetin
inject
emetin
omit
bp
edit
onward
still
avail
refer
standard
us
pharmacopoeia
websit
use
patient
beyond
scope
articl
suggest
stage
diseas
process
agent
emetin
use
treat
coronaviru
infect
earli
prolif
use
could
promot
resist
therapi
left
late
acut
respiratori
distress
develop
may
limit
effect
drug
relat
compound
emetin
test
vitro
coronaviru
sensit
dehydroemetin
develop
respons
cardiovascular
toxic
associ
emetin
dehydroemetin
structur
similar
emetin
recognis
lower
cardiovascular
risk
profil
emetin
use
replac
mani
year
dehydroemetin
elimin
tissu
quickli
may
explain
lower
toxic
howev
present
littl
sensit
data
use
dehydroemetin
antivir
agent
normal
situat
would
unexpect
antibacteri
compound
would
also
antivir
compound
unlik
mode
action
would
account
antibacteri
antivir
activ
emetin
affect
ribosom
protein
synthesi
yeast
shown
inhibit
viralrna
synthesi
may
overlap
antibacteri
antivir
mode
action
case
signific
structur
activ
relationship
gain
emetin
analogu
could
appli
develop
new
antivir
agent
emetin
select
list
drug
test
vitro
antivir
activ
coronavirus
see
tabl
drug
midrang
achiev
blood
level
obtain
literatur
blood
level
part
arbitrari
blood
level
mostli
determin
dose
vari
consider
base
condit
treat
also
limit
avail
studi
measur
blood
concentr
patient
ratio
blood
use
initi
rank
drug
potenti
clinic
signific
antivir
agent
coronavirus
drug
higher
ratio
deem
clinic
import
signifi
therapeut
antivir
concentr
like
achiev
normal
dose
system
prove
inadequ
especi
case
emetin
first
blood
level
vari
studi
one
studi
report
rang
level
achiev
anoth
record
mean
midpoint
rang
mean
differ
initi
indic
emetin
could
use
blood
ratio
approxim
see
tabl
realist
blood
concentr
use
mean
found
ratio
less
second
blood
level
take
consider
tissu
distribut
drug
basic
pharmacokinet
paramet
drug
volum
distribut
indic
tissu
uptak
use
identifi
drug
could
potenti
exhibit
favour
tissu
distribut
howev
volum
distribut
data
alon
suffici
determin
specif
tissu
accumul
high
volum
distribut
indic
drug
remov
plasma
goe
tissu
tissu
lipophil
drug
high
volum
distribut
littl
use
drug
partit
sole
adipos
tissu
similarli
high
distribut
bone
bisphosphon
would
also
littl
use
scenario
emetin
good
radiolabel
studi
clearli
show
bulk
emetin
distribut
tissu
also
signific
portion
went
lung
regardless
tabl
still
abl
highlight
drug
may
use
would
includ
agent
lopinavir
hydroxychloroquin
mycophenol
without
interferon
case
mycophenol
interferon
appear
therapeut
effect
treat
patient
mer
given
blood
ratio
calcul
trough
level
mycophenol
interferon
subtherapeut
immunosuppress
dose
may
still
antivir
efficaci
especi
use
combin
drug
hydroxychloroquin
lopinavir
anim
studi
interferon
appear
exhibit
antivir
activ
coronaviru
tabl
adapt
salata
seen
commerci
avail
cation
amphiphil
drug
screen
antivir
activ
often
exhibit
antivir
activ
differ
type
famili
virus
similar
possibl
number
agent
list
could
also
activ
viru
present
emetin
advantag
consid
togeth
make
attract
candid
significantli
inhibit
two
coronavirus
low
nanomolar
rang
potenti
achiev
satisfactori
plasma
level
administ
oral
produc
substanti
higher
concentr
affect
tissu
lung
known
effect
treat
entamoeba
histolytica
infect
inhibitori
concentr
hundr
time
higher
least
two
coronavirus
emetin
also
long
broad
histori
use
side
effect
well
known
manag
given
seriou
immedi
threat
viru
pose
long
partial
forgotten
histori
emetin
dehydroemetin
like
abil
emetin
reach
therapeut
concentr
within
lung
ipecac
emetin
analogu
consid
potenti
treatment
option
especi
vitro
studi
confirm
viru
sensit
agent
